Medial EarlySign

Early Detection of Life-threatening Conditions

Startup

Medial EarlySign is a Hod HaSharon-based startup in the Health Tech & Life Sciences sector, established in 2009. Early Detection of Life-threatening Conditions. The company has raised a total of $50M across 2 funding rounds, currently at the Mature stage. Medial EarlySign was founded by Ori Geva and Nir Kalkstein. Key investors include aMoon Fund, Viola Ventures, Nir Kalkstein, among 5 total investors. The company has 11-50 employees. Core technologies: Artificial Intelligence, Machine Learning.

With $50M in total funding, Medial EarlySign is a Mature-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Released. The company holds 1 patent.

$50M
Raised
2
Rounds
5
Investors
5
Team
2009
Founded
1
Patents
Sector & Technology
Health Tech & Life SciencesDigital HealthcareMedical Decision SupportDigital Medical DiagnosticsArtificial IntelligenceMachine Learning
At a Glance
Investors

5 investors total

Founders
In the News

29 articles covered by sources including www.prnewswire.com, www.themarker.com, www.mobihealthnews.com, www.geektime.com, nocamels.com.

www.prnewswire.com · Dec 19, 2024
/PRNewswire/ -- Medial EarlySign (earlysign.com), a pioneering company developing AI-based clinical predictive analytics, today announced a significant...
Read article ↗
Frequently Asked Questions
What does Medial EarlySign do?

Medial EarlySign’s AI-driven machine learning solutions empower healthcare stakeholders to keep patients healthier for extended periods. The company’s advanced models derive actionable clinical insights from massive datasets, helping improve patient outcomes, optimize diagnostics, and enhance medication management. Medial EarlySign's purpose-built development environment ensures precision decision-making, supported by peer-reviewed studies published by leading healthcare organizations worldwide. EarlySign helps clients identify people at high risk for conditions such as non-small cell lung cancer (NSCLC), lower GI disorders and cancers, prediabetic progression to diabetes, downstream diabetic complications, risk for flu and its complications, chronic kidney disease (CKD), COVID-19, and more. The company was named a cool vendor in "Cool Vendors in AI for Healthcare, 2017" by the Gartner Research Group and was a winner of the CMS AI Health Outcomes Challenge.

How much funding has Medial EarlySign raised?

Medial EarlySign has raised $50M in total funding across 2 rounds. The company is currently at the Mature stage. Key investors include aMoon Fund, Viola Ventures, Nir Kalkstein.

Who founded Medial EarlySign?

Medial EarlySign was founded in 2009 by Ori Geva (Co-founder & CEO), Nir Kalkstein (Co-founder & CTO).

What sector is Medial EarlySign in?

Medial EarlySign operates in Health Tech & Life Sciences, Digital Healthcare, Medical Decision Support, Digital Medical Diagnostics, with core technologies in Artificial Intelligence, Machine Learning. Target customers: Healthcare & Life Sciences, Healthcare, Providers.

Where is Medial EarlySign located?

Medial EarlySign is based in HaNagar St 6, Hod Hasharon, Israel, Center District. The company also has offices abroad.

View Full Profile Classic View Website ↗